tbuckley/cabot-search huggingface dataset:
Medical Schools in Canada
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Crutches
Authors: Raphael Karkowsky
Journal: Annals of Internal Medicine (2017)

On Being a Doctor1 August 2017CrutchesRaphael Karkowsky, MDRaphael Karkowsky, MDFrom Penn Delancey Internal Medicine, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M17-1147 Audio Reading - “Crutches” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Crutches," by R. Karkowsky. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail I follow him from behind. He walks unsteadily and, even with the use of crutches, his legs, largely paralyzed from polio as a child, are not strong enough to keep his feet from dragging across the floor. I breathe a sigh of relief when he makes it to the exam room without falling.Today's visit is unscheduled. “Mr. Devon is worried about his blood pressure,” my receptionist told me. We have a significant history together, so despite being short on time, I agreed to see him.We first met nearly 2 years ago. At that first office visit, he shook ... Author, Article, and Disclosure InformationAffiliations: From Penn Delancey Internal Medicine, Philadelphia, Pennsylvania.Corresponding Author: Raphael Karkowsky, MD, Penn Delancey Internal Medicine, 800 Walnut Street, 17th Floor, Philadelphia, PA 19107; e-mail, Raphael.[email protected]upenn.edu. PreviousarticleNextarticle Advertisement Audio Reading - “Crutches” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Crutches," by R. Karkowsky. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 1 August 2017Volume 167, Issue 3Page: 212KeywordsAlcoholsBlood pressureEmotionsMalnutritionMemoryPoliomyelitisSaltsShouldersTouchWheelchairs ePublished: 1 August 2017 Issue Published: 1 August 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
Authors: Jason L. Eriksen, Sarah A. Sagi, Tawnya E. Smith, Sascha Weggen, Pritam Das, D.C. McLendon, Victor V. Ozols, Kevin W. Jessing, Kenton H. Zavitz, Edward H. Koo, Todd E. Golde
Journal: Journal of Clinical Investigation (2003)

Epidemiologic studies demonstrate that long-term use of NSAIDs is associated with a reduced risk for the development of Alzheimer disease (AD). In this study, 20 commonly used NSAIDs, dapsone, and enantiomers of flurbiprofen were analyzed for their ability to lower the level of the 42-amino-acid form of amyloid β protein (Aβ42) in a human H4 cell line. Thirteen of the NSAIDs and the enantiomers of flurbiprofen were then tested in acute dosing studies in amyloid β protein precursor (APP) transgenic mice, and plasma and brain levels of Aβ and the drug were evaluated. These studies show that (a) eight FDA-approved NSAIDs lower Aβ42 in vivo, (b) the ability of an NSAID to lower Aβ42 levels in cell culture is highly predicative of its in vivo activity, (c) in vivo Aβ42 lowering in mice occurs at drug levels achievable in humans, and (d) there is a significant correlation between Aβ42 lowering and levels of ibuprofen. Importantly, flurbiprofen and its enantiomers selectively lower Aβ42 levels in broken cell γ-secretase assays, indicating that these compounds directly target the γ-secretase complex that generates Aβ from APP. Of the compounds tested, meclofenamic acid, racemic flurbiprofen, and the purified R and S enantiomers of flurbiprofen lowered Aβ42 levels to the greatest extent. Because R-flurbiprofen reduces Aβ42 levels by targeting γ-secretase and has reduced side effects related to inhibition of cyclooxygenase (COX), it is an excellent candidate for clinical testing as an Aβ42 lowering agent.
OP0362 Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis
Authors: D. Leonard, E. Svenungsson, J. Dahlqvist, A. Alexsson, L. Ärlestig, K.E. Taylor, J.K. Sandling, C. Bengtsson, M. Frodlund, A. Jönsen, S. Eketjäll, K. Jensen-Urstad, I. Gunnarsson, C. Sjöwall, A.A. Bengtsson, M.-L. Eloranta, A.-C. Syvänen, S. Rantapää-Dahlqvist, L.A. Criswell, L. Rönnblom
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Patients with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA) have increased risk of cardiovascular disease (CVD). <h3>Objectives</h3> We investigated whether single nucleotide polymorphisms (SNPs) at autoimmunity risk loci were associated with CVD in SLE and RA. <h3>Methods</h3> SLE patients (n=1045) were genotyped using the 200K Immunochip SNP array (Illumina). The allele frequency was compared between patients with and without different manifestations of CVD. Results were replicated in a second SLE cohort (n=1043) and in an RA cohort (n=824). We analysed publically available genetic data from the general population, performed electrophoretic mobility shift assays and measured cytokine levels and occurrence of anti-phospholipid antibodies (aPLs). <h3>Results</h3> We identified two new putative risk loci associated with increased risk for CVD in two SLE populations, which remained after adjustment for traditional CVD risk factors. An <i>IL19</i> risk allele was associated with stroke/myocardial infarction in SLE (OR 2.3 (1.5–3.4), p=8.5×10–5) and RA (OR 2.8 (1.4–5.6), p=3.8×10–3), meta-analysis (OR 2.5 (2.0–2.9), p=3.5×10–7), but not in population controls. The<i> IL19</i> risk allele affected protein binding and SLE patients with the risk allele had increased levels of plasma-IL10 (p=0.004) and aPL (p=0.01). An <i>SRP54-AS1</i> risk allele was associated with stroke/transient ischaemic attack in SLE (OR 1.7 (1.3–2.2), p=2.5×10–5) but not in RA. The <i>SRP54-AS1</i> risk allele is an expression quantitative trait locus for four genes. <h3>Conclusions</h3> The <i>IL19</i> risk allele was associated with stroke/myocardial infarction in SLE and RA, but not in the general population, indicating that shared immune pathways may be involved in the CVD pathogenesis in inflammatory rheumatic diseases. <h3>Disclosure of Interest</h3> None declared
Reproductive toxicology. Sodium saccharin.
Authors: James Lamb, Dushyant Gulati, Valerie Russell, Leta Hommel, K Poonacha, P Sabharwal
Journal: Environmental Health Perspectives (1997)

0 11 NNa \\0 Sodium saccharin (NaSac), used as an artificial sweetener since the late 1800s, was tested for potential effects on reproduction and fertility in Swiss CD-1 mice using the RACB protocol (Morrissey et al., Fundam Appl Toxicol 13:747-777 [1989]).Data on food and water consumptions, body weights, and clinical signs from the doserange-finding study (Task 1) were used to set exposure concentrations for the con- tinuous cohabitation phase (Task 2) at 1.25, 2.5, and 5% weight per volume in the drinking water.While water con- sumption was decreased at the high dose by approximately 10 to 20%, it was increased at the low and middle dose levels by approximately 40 and 20%, respectively.Consequently, the high dose animals gained slightly less weight during Task 2. Measures of body weights and water consumption allowed the calculation of daily exposure estimates: 3.5, 5.9, and 8.1 g/kg/day.In Task 2, three, zero, one, and eight mice died in the control, low, middle, and high dose groups, respectively.The
US Malaria Cases Reach 40-Year High
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The British Society of Gastroenterology diamond jubilee meeting. Brighton, 18-21 March 1997. Abstracts.
Authors: H Pylori, ) Gillen, K Wirz, ; Mccoll, Dr Foster, J Atherton, R Twells, C Hawkey, R Peek, T Cover, M Blaser, Oesophageal Adenocarcinoma, D Ce Grinley, A Loft, Nwokolo Morris, C Inha, L Treharne, D Murray, M Williams, Philip Dew, Llanelli Hospital, Neema Rashid, Irvin Modlin, Laura Tang, Nicholas Wrijht
Journal: Gut (1997)

Iltroduction: Proton pump inhibitors (PPIs) are very commonly used drugs.Recent data indicate that they cause more marked elevation of intragastric pH in H.P-infected individuals.It is not clear whether this is due to a neutralising effect of ammonia produced by H. pylori urease or to a more marked inhibition of acid secretion.Am: To assess the effet of H. pylori status on acid secretion during PPI therapy.Subjects and Methods: I8 H.P -ve and I) H.P.+ve healthy volunteers were studied.H. pylori status was confirmed by the 14C-urea breath test.Prior to commencing the PPI therapy, basal acid output, acid output to gastrin releasing peptide (40pmoUkg/h) (GRP) and maximal acid output to (MAO) were measured on separate days.Omeprazole 40mg/day was then taken in the morning daily for eight weeks. Onseparate mornings in the last two weeks ol this course, the acid secretion studies were repeated (24 hours after the last dose).H.PY ngative Pre-On o Omep.Omep. Inhib. asal intragastric plt 1.61 3.74* Basal acid output (mnol/h) GRP acid output (mmol/h) H.P. pIsitivc Pre-On O Omep.Omep.Inhib.1.50 8.04 3.4 0.3* 82%9 3.2 0.0 100%.9.6 3.8* 64t1 14.2 0.0 100% MAO(;.(nmoVl/h) 36.0 18.2* 5290 34.6 7.1 80% Values are mediarms.*Indica(es difference fr(wn H.P+ve at p<0.05.1,ifi-ion and Conclusions: This study indicates that the inhibition of gastric tcid secretion produced by PPI therapy is much more profound in H.P+ve individuals.The magnitude of this effect cannot be explained by the neutralising effect Of bactcrial ammonia.It may be explained by the body gastritis which develops in H.P.+vc subjects during PPI therapy impairing acid secrctory function and.thus augmenting the effect of the drug.This profound suppression of acid secretion may have deleterious effects by facilitating gastric bactcrial colonisation and consequently predisposing to gastric carcinoma.Eradication of H. pylori may be appropriate prior to long-tcrm PPI therapy, but this may reducc the efficacy of PPI therapy in reflux disease.
The Depression Rating Scale
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Biologic and clinical significance of CD7 expression in acute myeloid leukemia
Authors: Anurag Saxena, David P. Sheridan, Robert T. Card, A.M. McPeek, C.C. Mewdell, Leonard F. Skinnider
Journal: American Journal of Hematology (1998)

CD7 antigen, a T-cell lineage associated antigen, is expressed in a minority of patients with acute myeloid leukemia (AML). The biologic and clinical significance of this finding is not clearly established. In this retrospective study of patients with de novo acute myeloid leukemia, we have identified CD7 expression and analyzed its association with markers expressed early in hemopoietic ontogeny and clinical parameters. Among 60 consecutive AML patients, we found six (10%) expressing CD7 on leukemic cells. There were five males and one female and the mean age was 59.6 years (age range: 32–76 years) with no demographic peculiarities. The FAB subtypes were: M0 (2), M1 (1), M2 (1), and M4 (2). CD7 expression was associated with immature antigens CD34, HLA-DR, and terminal deoxynucleotidyl transferase (TdT) and antigen receptor gene rearrangements (rearrangements of T-cell receptor gamma chain in 6/6 and immunoglobulin heavy chain in 2/6). Hepatomegaly was present in three and this was associated with splenomegaly with lymphadenopathy in one patient. Mediastinal or central nervous system involvement was absent. Complete remission was achieved in two patients with standard chemotherapy; one of these is in remission and alive (5 years later), while one died following relapse 9 months later. Three patients had significantly lower response to standard therapeutic regimen (two died during induction and one died 7 months later without ever achieving complete remission). One patient has been excluded in determining the prognostic significance of CD7 due to early death. Our results suggest origin of CD7+ AML from early hemopoietic precursors and indicate biologic aggressiveness in a significant proportion of patients. We suggest evaluation of CD7 in all patients with AML at the time of diagnosis in view of poor clinical outcome. Am. J. Hematol. 58:278–284, 1998. © 1998 Wiley-Liss, Inc.
<i>Annual and Analytical Cyclopaedia of Practical Medicine</i>by Charles E. De M. Sajous, M. D., and one hundred associate editors, assisted by corresponding editors, collaborators and correspondents. Illustrated with chromo-lithographs, engravings and maps. Volume VI. (<i>Philadelphia, New York, Chicago, F. A. Davis Co., Publishers, 1901</i>)
Journal: American Journal of Psychiatry (1901)
Organ-Specific Effect of Dry Sicca Cell Preparations
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chenotherapy for gallstone dissolution. II. Induced changes in bile composition and gallstone response
Authors: A. F. Hofmann
Journal: JAMA (1978)

Changes in bile saturation and biliary bile acid composition in patients with gallstones who received chenodeoxycholic ("chenic") acid, cholic acid, or placebo were measured. Chenodeoxycholic induced bile desaturation; this effect was attributable solely to a decrease in the proportion of cholesterol. By gas chromatography, chenodeoxycholic acid increased substantially in the biliary bile acids of patients receiving it, and by mass spectrometry, no unusual bile acids were detected in appreciable amounts. Changes in bile saturation and biliary bile acid composition were then related to chenodeoxycholic acid dosage, and all of these variables were, in turn, related to gallstone response. In general, patients whose gallstones dissolved ingested a higher dose of chenodeoxycholic acid or had bile that contained a higher proportion of this acid and it was more unsaturated, but there were many exceptions, casting doubt on the value of a single analysis of fasting-state bile for predicting gallstone dissolutions. The major factor influencing response, provided dosage is adequate, appears to be gallstone type. Nonetheless, the proportion of chenodeoxycholic acid in biliary bile acids can probably be used to infer patient compliance. (<i>JAMA</i>239:1138-1144, 1978)
Antiperinuclear factors are present in polyarthritis before ACR criteria for rheumatoid arthritis are fulfilled
Authors: A. M T H BOERBOOMS;, J-M BERTHELOT
Journal: Annals of the Rheumatic Diseases (1997)

Pain in the rheumatic diseasesWe were very interested to read Professor Croft's article 1 about pain in the rheumatic diseases because we are interested in studying the relation between patients' perception of disease and objective signs. 2 In the daily management of a cohort of approximately 600 patients with inflammatory arthritis at Poole Hospital we noticed a dissociation between reported pain and objective measures of disease activity in a number of patients.To further study this phenomenon we randomly selected a sample of 100 patients with rheumatoid arthritis (mean (SD) age = 63 (12) years, 73% rheumatoid factor positive).We looked at the pattern of change of reported pain (10 cm visual analog scale (VAS)), number of swollen joints (EULAR 28 articular index), and serum C reactive protein (CRP, normal <10 mg/l) in the previous two years.We identified a close linear relation in 72 patients.In 18 patients pain was repeatedly reported at not less than 20 mms VAS despite no evidence of disease activity (CRP <10 mg/l and swollen joint count = 0) at any point during their follow up.In 10 patients pain was repeatedly scored as absent despite disease activity markers reflecting joint inflammation (CRP >15 mg/l, with or without >2 swollen joints).Fifteen of 18 patients showing pain but no disease activity were rheumatoid factor positive and there was no obvious diVerence in the degree of joint deformity clinically although detailed assessment of joint damage radiologically was not made.These preliminary data support our contention that, in about one third of patients followed up in a district general hospital, there is a dissociation between reported pain and objective signs of joint inflammation.These diVerences may be related to joint damage in the patients with pain but no disease activity but cannot be so explained in those patients with disease activity but no pain.A more detailed analysis of these patients may reveal the reasons for this dissociation.In the meantime we suggest that rheumatologists might consider managing pain separately from disease activity in some of their patients.We also urge caution in interpreting summated disease activity indices that include pain and joint tenderness as major parts of their score.
Sugary Drinks: A Daily Downfall
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Transacetabular herniation of small bowel and right adnexa. An unusual complication of hip arthroplasty
Authors: R. M. Gore
Journal: JAMA (1983)

DURING the past 30 years, hip arthroplasty and total hip replacement have become increasingly popular in the treatment of severe degenerative and rheumatoid arthritis, intertrochanteric femoral neck fractures, and aseptic necrosis of the femoral head.<sup>1</sup>This procedure, which has helped rehabilitate thousands of patients, is associated with many complications that result from either mechanical or technical failures, infection, or the general complications of major surgery.<sup>2,3</sup>We present an unusual and previously unreported iatrogenic complication of hip surgery: herniation of the small bowel and right adnexa into the right hip joint through a bony defect in the acetabulum after a Girdlestone procedure. A brief review of the complications of total hip arthroplasty is also presented. <h3>Report of a Case</h3> A 31-year-old woman who had undergone a right total hip arthroplasty for degenerative joint disease secondary to Legg-Calvé-Perthes disease presented with an infected right hip. Since its implantation one year